Contact
searchSearch
HMP Global
Sponsored Video

Eluvia DES: Durability by Design, Proven by Level 1 Evidence

Robert A. Lookstein, MD
Kumar Madassery, MD
Keith Sterling, MD
10/13/2026

Listen as Dr Robert Lookstein and Dr Kumar Madassery discuss the clinical evidence supporting Eluvia DES, its performance in complex femoropopliteal disease, and the role of durable drug-eluting therapy in reducing reintervention burden and improving patient care.

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.
 

Related Content

Dr Eric Secemsky
Sponsored Video
Revisiting Paclitaxel: Where Does the Evidence Stand Today?
10/13/2026
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI; Marianne Brodmann, MD; Keith Sterling, MD
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Drs Secemsky, Brodmann, and...
10/13/2026
Vascular Disease Management
Case Report
Successful Recanalization of a Superficial Femoral Artery Chronic Total Occlusion Using the Santreva-ATK Endovascular Revascularization Catheter
10/12/2026
Angelo Caputi Zuniga, MD; Sudhir Mungee, MD
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report discusses a...
10/12/2026
Vascular Disease Management
Bioresorbable Scaffolds
REVA Medical Announces Motiv Sirolimus-Eluting Bioresorbable Vascular Scaffold Live Case and Late-Breaking BTK Trial Results at VIVA26
10/08/2026
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical,...
10/08/2026
Cath Lab Digest
Lower-Extremity & Stroke Intervention
VIVA26: New Results From AGILITY, PERFORMANCE II, and XTRACT
10/07/2026
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26...
10/07/2026
Cath Lab Digest

Stay in the Know

Vascular Disease Management Newsletter

News

Deep Learning
Deep Learning Model Predicts Hepatocellular Carcinoma Progression Following Transarterial Chemoembolization
10/09/2026
Laura Simson, MA
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining...
10/09/2026
Vascular Disease Management
AngioDynamics
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
10/08/2026
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS...
10/08/2026
Vascular Disease Management
Bioresorbable Scaffolds
REVA Medical Announces Motiv Sirolimus-Eluting Bioresorbable Vascular Scaffold Live Case and Late-Breaking BTK Trial Results at VIVA26
10/08/2026
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical,...
10/08/2026
Cath Lab Digest
Lower-Extremity & Stroke Intervention
VIVA26: New Results From AGILITY, PERFORMANCE II, and XTRACT
10/07/2026
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26...
10/07/2026
Cath Lab Digest
Chronic Venous Disease
Medtronic Announces New Prospective, Global Clinical Evidence From the Spectrum Program for VenaSeal™ Closure System in Advanced Chronic Venous Disease
10/07/2026
10/07/2026
Vascular Disease Management
Peripheral Intervention
VIVA26: New Results From POWER PAD II, DISRUPT PAD BTK II, PROMISE III, ELEGANCE, and a TCOT Trial
10/07/2026
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies...
10/07/2026
Cath Lab Digest
Pulmonary Embolism
VIVA26: New Results From HI-PEITHO, STORM-PE, and TRUST
10/07/2026
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Three late-breaking VIVA26...
10/07/2026
Cath Lab Digest
Peripheral Intervention
VIVA26: New Results From SELUTION4SFA, SirPAD, SUCCESS PTA, CADET-PAD, Esprit BTK, and MOTIV BTK
10/07/2026
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Six late-breaking VIVA26 studies...
10/07/2026
Cath Lab Digest
iliac artery disease
VIVA 2026: BD's Revello Covered Stent Shows 97.2% Primary Patency in AGILITY Trial
10/07/2026
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of...
10/07/2026
Cath Lab Digest
Pulmonary Embolism
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
10/07/2026
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Wearable-derived data provide...
10/07/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use